The agent gathered a functional understanding of Polyrizon's business by assembling fragments from the website homepage, contact page, technology platform page, news/press releases, and investor relations portal, supplemented by web search for market context. The site's main pages are navigable but minimalist—standard navigation URLs (/about, /products) returned 404s, forcing the agent to rely on the homepage tagline, a dedicated technology page, and press releases to construct the narrative. Pricing was genuinely unavailable because the company is pre-commercial, which the agent correctly identified rather than misrepresenting.

• ›Step [1] homepage meta description provided the core positioning ('biotech company, focused on the development and commercialization of innovative intranasal products based on the Company's technology platforms'), which anchored the entire answer.
• ›Step [12] (/capture-contain-tm) was the only page on the main domain that deeply explained a technology platform; this single page bore most of the technical differentiation content.
• ›Step [13] (news/press releases) supplied product names (NASARIX™, PL-14), clinical trial status, and partnership information—not surfaced on the homepage or via standard navigation.
• ›Step [5] (contact page) provided only logistical details (address, email, phone); no business model or positioning information.
• ›Step [15] (investor.polyrizon-biotech.com) was accessible but the agent did not cite it in final sources, suggesting it may have contained financial/cap table data irrelevant to the task.
• ›The site's navigation structure is broken (404 on /about and /products), pushing the agent toward guessing URLs and relying on the sitemap to discover content.
• ›Web searches (steps [9], [14], [16]–[18]) were necessary to contextualize Polyrizon's stage (clinical trial phase), partnerships, and competitive positioning—this information was not present or easily surfaced on the website itself.
• ›Pricing was correctly identified as absent because the product is not yet commercialized; the agent did not hallucinate pricing and instead explained why it was unavailable.